Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.
Hydroxychloroquine (HCQ) has been used as a supportive therapy for IgA nephropathy (IgAN). We aimed to determine the long-term efficacy and safety of HCQ therapy in patients with IgAN.A total of 180 patients with IgAN who had received HCQ therapy for at least 1 year were enrolled in this study. The changes in proteinuria and the estimated glomerular filtration rate (eGFR) were analyzed during the follow-up period.The level of proteinuria decreased from 1.69 [1.24, 2.30] to 1.01 [0.59, 1.74] g/day (- 37.58 [- 57.52, 8.24] %, P
Authors: Chen Tang, Ji-Cheng Lv, Su-Fang Shi, Yu-Qing Chen, Li-Jun Liu, Hong Zhang